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The local scenario
Minami et al [1] highlighted the relative high rate of local
tumor progression (LTP) after radiofrequency ablation
(RFA) for unresectable colorectal liver metastases (CRLM),
ranging from 8.8 to 40%. Furthermore, the phase II CLOCC
trial (NCT00043004) results demonstrated a significant im-
provement in disease-free survival (DFS) and overall survival
(OS) in case of a combined approach compared with chemo-
therapy alone [2]. Thus, low LTP rate is desirable since it
ultimately impacts on OS; an effective and complete local
therapy with subsequent low LTP rate is the primary and
prominent goal for interventional radiologists. For this pur-
pose, both technical skills (improved by technological ad-
vancements such as ablation confirmation software develop-
ment) and oncological expertise are required. Indeed, LTP
rates are affected by adequate ablation margins (required mar-
gins of at least 5 mm in CRC metastases [3]) and patients’
selection considering tumor biological characteristics [4].
Apparently, with this approach, the local interventions do
not seem to be different from a surgical technique (with the
goal of free resection margin and careful selection of surgical
candidates).
However, ablation therapy is relevantly different from sur-
gical resection; ablation therapies leave tumor debris in situ
which potentially has a huge impact on short- and long-term
outcomes. Actually, on the one hand, it has been demonstrated
that ablation may induce extra-target tumor growth and local
recurrence with a more aggressive tumor phenotype [5]. On
the other hand, as it has been underlined in the review article
by Minami et al [1], several studies revealed that the ablation
therapy positively stimulates the innate and adaptive immune
system locally and globally. The understanding of interaction
between the tumor debris left by the ablation and the immune
system and the possible presence of minimal residual disease
is a key point for further investigation in interventional onco-
logical procedures.
The systemic scenario
In a systemic scenario, in the last two decades, target therapies
have revolutionized cancer management [6]. Furthermore, in
recent years, immunotherapy represented the major break-
through in clinical cancer care with significant improvement
in OS inmany advanced-stage cancers (lung, melanoma, blad-
der, renal cell carcinoma, etc.). With the term immunotherapy,
we include a wide range of treatments: cytokines, immune
checkpoint inhibitors (ICIs), cancer vaccines, and cell-based
immunotherapy (infusion of ex vivo–activated tumor-specific
T cells). ICIs are both target therapies and a type of immuno-
therapy; they act by stopping the tumor immune suppression
and can be considered today the most used and effective im-
munotherapeutic agents in clinical practice. Indeed, PD1, PD-
L1, and anti CTLA4 inhibitors showed promising clinical out-
comes and have been approved for many cancer treatments
[7].
The Bglocal^ approach
In the future, one of the major challenges for interventional
radiologists will be obtaining a comprehensive knowledge
regarding the potential synergistic effect between interven-
tional local treatments and systemic, global treatments and
translating it into clinical practice.
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The term Bglocal^ is a linguistic blend of two words, global
and local, and it has had a large spread in social and economic
spheres in recent years. It means, by definition, to reflect or to
be characterized by both local and global considerations and
analyze the bi-directional influences between local and global
systems [8].
Similarly, in a clinical oncological scenario, the term
Bglocal^ can be used to define the research field concerning
interactions between local and systemic therapies. As well as
in economical sciences, interactions between local interven-
tions and systemic oncological treatments can be bi-
directional and beneficial for both fields.
Seminal studies (recently summarized in a white paper
from the Society of Interventional Oncology [9]) have already
demonstrated that this bi-directional interaction exists and
should be better investigated by larger preclinical and clinical
studies. Indeed, local interventions may boost the efficacy of
systemic therapies by increasing the activation of tumor-
specific T cells in combination with anti-CTLA4 therapies;
vice versa, systemic therapies will be a useful aid to local
therapies in case of persistence of minimal residual disease
after ablation.
Future developments
Future researches will require to focus on the beneficial treat-
ments for patients such as particular interventions or com-
bined treatments and also to discover the correct timing of
sequential treatments.
In the near future, three major research fields can be
outlined:
1. BFrom bench to bedside^ research on immune tumor mi-
cro-environment: several data are already present in the
literature; however, it requires more effort by the interven-
tional community to better understand the molecular
mechanisms behind residual disease and immune system
stimulation of ablation treatments;
2. The detection of minimal residual disease: the de-
velopment of biomarkers to early predict recurrence
before conventional cross-sectional imaging will pa-
ve the way to a correct selection of patients in case
of combined treatments with systemic therapies.
Development of liquid biopsy tools (early detection
of circulating tumor materials with sensitive technol-
ogies) and radiomics analysis of tumors and ablation
area will be of great value in this regard;
3. Timing of sequential treatments: after comprehension of
the molecular mechanisms and selection of the correct
patients through sensitive technologies, trials should be
designed to validate the best Bglocal^ approach for the
right patient.
In conclusion, today more than ever, the linguistic expres-
sion Bthink globally, act locally^ (often been used within the
context of Bglocalization^) perfectly suits the urgent actions
that interventional radiologists should take in order to inte-
grate the local interventions within the systemic clinical
scenario.
Interventional radiologists are asked to act in this multidis-
ciplinary setting (together with medical oncologists, radiation
oncologists, and surgical oncologists) as interventional oncol-
ogists, with a strong clinical background and patient-oriented
mentality. This is the only way in which interventional oncol-
ogy will truly grow up and will be fully recognized as the
fourth pillar of oncology.
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